COX Nicox SA

Number of voting rights as of January 9, 2023

Number of voting rights as of January 9, 2023

Nicox SA 

Société anonyme with a registered capital of € 50,100,448 

Head Office: 

DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis  

R.C.S. GRASSE 403.942.642 

On January 9, 2023, 

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS 

(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) 

 As of January 09, 2023 
Total number of shares composing the share capital 50,100,448 
Total number of voting rights 50,100,448 
Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights 50,100,448 

--------------- 

 

Phone: 00 

Fax : 99 

 

Attachment



EN
09/01/2023

Underlying

COXNicox SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces Shareholder Q&A Webpage Available

Nicox Announces Shareholder Q&A Webpage Available Press Release Nicox Announces Shareholder Q&A Webpage AvailableAugust 26, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, , including information on the most frequently asked questions for shareholders in the form of a Q&A about Nicox and its business. The Q&A page can be reached here: Any investor questions can be addressed to .About NicoxNicox SA is an internat...

17h / 32m 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur s...

Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet Communiqué de presseNicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet26 août 2025 – publication à 7H30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui qu’une nouvelle page « Questions-Réponses » est disponible sur le site internet de la Société, , contenant des informations aux questions les plus fréquentes des actionnaires sur Nicox et son acti...

17h / 32m 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial...

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and ChinaNCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p

August 21, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox annonce des résultats positifs pour NCX 470 dans l’étude de Phas...

Nicox annonce des résultats positifs pour NCX 470 dans l’étude de Phase 3 Denali chez des patients atteints de glaucome Communiqué de presseNicox annonce des résultats positifs pour NCX 470 dans l’étude de Phase 3 Denali chez des patients atteints de glaucome L’atteinte du critère principal dans les deux études Denali et Mont Blanc, la première étude de Phase 3 pour NCX 470, remplit les exigences d’efficacité requises pour une approbation aux États-Unis et en Chine NCX 470 a également montré une supériorité sur le latanoprost dans la réduction de la pression intraoculaire (PIO) par rapport...

August 21, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Extends Existing Flexible Equity Financing

Nicox Extends Existing Flexible Equity Financing Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 August 08, 2025 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of the PACEO1 equity line of financing entered into with Vester Finance on March 5, 2025, with an additional maximum of 5,000,000 s...

August 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch